SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aventis Pharma declines on reporting poor Q1 numbers

04 May 2012 Evaluate

Aventis Pharma is currently trading at Rs. 2100.00, down by 38.10 points or 1.78% from its previous closing of Rs. 2138.10 on the BSE.

The scrip opened at Rs. 2110.00 and has touched a high and low of Rs. 2130.80 and Rs. 2077.00 respectively.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 2429.95 on 02-Jan-2012 and a 52 week low of Rs. 1917.00 on 27-May-2011.

Last one week high and low of the scrip stood at Rs. 2,280.00 and Rs. 2,077.00 respectively. The current market cap of the company is Rs. 4875.58 crore.

The promoters holding in the company stood at 60.40% while Institutions and Non-Institutions held 27.26% and 12.34% respectively. 

Aventis Pharma’s net profit has declined by 20.75% to Rs 40.1 crore for the first quarter ended March 31, 2012, over the same period previous year. The company reported a net profit of Rs 50.6 crore in the same period of previous year. The profit of the quarter has been impacted due to the amortisation costs relating to the brands and technical know how acquired in 2011 from Universal Medicare and lower interest income as a result of the above investment.

The pharmaceutical company’s net sales rose to Rs 322.5 crore for the first quarter ended March 31, 2012, as compared to Rs 276.3 crore in the corresponding period of last year.

The company's board has recommended a final dividend of Rs 29 per share of a face value of Rs 10 for the year ended December 31, 2012.

Sanofi India Share Price

3578.55 18.75 (0.53%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×